IQVIA partnered with a pharmaceutical company to improve patient access to immunotherapy through a comprehensive Patient Access Program. Patients faced barriers such as high out-of-pocket costs, limited treatment understanding, and missed doses. IQVIA delivered coordinated financial assistance, education, proactive follow-ups, and stakeholder engagement across providers and payers. The program reduced average time to treatment initiation to 3–4 days and achieved high adherence and persistence rates. Patients reported greater clarity, confidence, and continuity of care. Deployed across 20 countries and 30 oncology indications, the program showcased IQVIA’s ability to remove barriers and improve outcomes at scale.

Join for free to read